EuBiologics Co., Ltd.
206650.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$309.21B
Close$
Share Statistics
| Market cap | $309.21 Billion |
|---|---|
| Enterprise Value | $319.52 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1127.16 |
| Beta | 0.19 |
| Outstanding Shares | 36,731,593 |
Return
| Return on Equity | 15.98% |
|---|---|
| Return on Assets | 12.13% |
| Return on Invested Capital | 23.02% |
Valuation & Multiples
| P/E Ratio | 10.64 |
|---|---|
| PEG | -363.08 |
| Price to Sales | 2.43 |
| Price to Book Ratio | 1.64 |
| Enterprise Value to Revenue | 2.61 |
| Enterprise Value to EBIT | 6.81 |
| Enterprise Value to Net Income | 11 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About EuBiologics Co., Ltd.
323 employees
CEO: Yeong-Ok Baik Established in 2010 and based in Seoul, South Korea, EuBiologics Co., Ltd. is a biopharmaceutical company dedicated to developing and supplying essential vaccines for epidemics and antibiotic resistance within the country. Its product po...